Polio

Polio
Name	Poliomyelitis
Field	Infectious disease

Polio Poliomyelitis is an acute infectious disease caused by poliovirus, historically responsible for epidemics of flaccid paralysis and long-term disability. It affected communities across Europe, United States, India, Egypt, and Brazil before widespread immunization programs led by organizations such as the World Health Organization, Centers for Disease Control and Prevention, and UNICEF drastically reduced incidence. Polio’s social and cultural impact included influences on figures like Franklin D. Roosevelt, institutions such as the March of Dimes, and international initiatives including the Global Polio Eradication Initiative.

History

Early descriptions of paralytic illness consistent with poliomyelitis appear in accounts from Ancient Egypt and the writings of Hippocrates, but modern recognition emerged in the 19th and early 20th centuries with outbreaks in Europe and the United States. The bacteriologist Heinrich Irenaeus Quincke and clinicians like Jakob Heine contributed to early nosology; the viral etiology was established by researchers such as Karl Landsteiner and Ernest W. Goodpasture and refined through virology work by Albert Sabin and Jonas Salk. Public mobilization for vaccine development involved philanthropic and political actors including Eleanor Roosevelt, the Rockefeller Foundation, and the National Foundation for Infantile Paralysis (later known as the March of Dimes). Mass vaccination campaigns in the mid-20th century transformed public health, intersecting with initiatives for smallpox eradication led by WHO and immunization programs promoted by UNICEF and bilateral efforts from countries such as United Kingdom and Soviet Union.

Virology and Pathogenesis

The causative agents are positive-sense single-stranded RNA viruses in the genus Enterovirus of the family Picornaviridae. Three serotypes—historically designated types 1, 2, and 3—exhibit differing neuropathogenic profiles documented in laboratory work by Albert Sabin and Jonas Salk. After ingestion, poliovirus replicates in the oropharynx and gastrointestinal tract, with viremia enabling access to the central nervous system where it can infect anterior horn motor neurons in the spinal cord, a pathogenic mechanism studied in models such as the mouse model and documented in neuropathological work by investigators from institutions like the Pasteur Institute and Johns Hopkins Hospital. Viral entry and tropism involve host receptors characterized by molecular biology teams at universities including Harvard University and University of California, San Francisco.

Transmission and Epidemiology

Poliovirus spreads primarily by the fecal–oral route and, less commonly, via oropharyngeal secretions; transmission dynamics were elucidated in epidemiological studies from Sweden, Norway, and epidemic analyses in United States cities. Endemic and epidemic patterns varied with sanitation, urbanization, and population immunity, with high-burden regions historically including Egypt, India, and parts of Africa until large-scale campaigns by WHO and the Global Polio Eradication Initiative reduced circulation. Surveillance strategies utilize acute flaccid paralysis reporting, environmental sewage sampling pioneered in public health laboratories at Centers for Disease Control and Prevention and national institutes like India's National Polio Surveillance Project.

Clinical Presentation and Complications

Clinical manifestations range from asymptomatic infection to abortive poliomyelitis with non-specific febrile illness, to aseptic meningitis, and to paralytic disease causing flaccid paralysis; these clinical spectra were characterized in clinical series from hospitals such as Boston Children's Hospital and Great Ormond Street Hospital. Paralytic involvement often presents as asymmetric weakness, hyporeflexia, and muscle atrophy, sometimes progressing to respiratory failure requiring ventilatory support introduced via innovations like the iron lung and modern intensive care practices at centers including Mayo Clinic. Long-term complications include post-polio syndrome, described in longitudinal cohorts from University of Toronto and Duke University, characterized by new weakness, fatigue, and pain decades after acute infection.

Diagnosis and Treatment

Diagnosis relies on clinical assessment of acute flaccid paralysis, laboratory confirmation via viral culture or polymerase chain reaction of stool and throat specimens developed in reference laboratories such as CDC and Institute Pasteur, and serology in selected contexts. Neuroimaging at institutions like Massachusetts General Hospital can assist in differential diagnosis. Treatment is supportive: respiratory support, physical therapy pioneered by rehabilitation programs at Shriners Hospitals for Children and orthotic management developed with centers like Hospital for Special Surgery. Antiviral agents have been investigated in research at National Institutes of Health but no specific universally approved curative antiviral exists for paralytic disease.

Prevention and Vaccination

Prevention relies on immunization with inactivated poliovirus vaccine developed by Jonas Salk and oral attenuated vaccine developed by Albert Sabin. Mass immunization strategies—implemented through campaigns by WHO, UNICEF, GAVI, the Vaccine Alliance, and national ministries of health in countries such as Nigeria, Pakistan, and Afghanistan—use schedules and supplementary immunization activities to achieve herd immunity. Cold chain logistics and vaccine safety monitoring are coordinated with agencies including Pan American Health Organization and regulatory bodies such as the European Medicines Agency.

Public Health and Eradication Efforts

Global eradication efforts spearheaded by the Global Polio Eradication Initiative, launched with partners including WHO, Rotary International, CDC, and UNICEF, have driven reduction in wild poliovirus cases by >99% since 1988, with milestones documented in reports from World Health Assembly meetings and national elimination declarations by United States and Region of the Americas. Challenges persist in access, conflict zones such as areas affected by operations in Syria and Yemen, vaccine-derived poliovirus events studied by teams at CDC and WHO, and surveillance gaps addressed through partnerships with academic centers such as London School of Hygiene & Tropical Medicine and Imperial College London. Continued political commitment, funding from philanthropic actors including the Bill & Melinda Gates Foundation, and integration with broader immunization and health systems remain critical to achieving certification of global eradication.

Category:Viral diseases